(S)-2-(Boc-Amino)non-8-Enoic Acid CAS 300831-21-4 Purity >98.0% (GC) ee >99.0% Paritaprevir Intermediate Factory

Incazelo emfushane:

Igama: (S)-2-(Boc-Amino)non-8-Enoic Acid

I-CAS: 300831-21-4

Ubumsulwa: >98.0% (GC)

Yebo: >99.0%

Ukubukeka: Uketshezi Olunsundu

Abaphakathi kweParitaprevir (CAS: 1216941-48-8)

E-Mail: alvin@ruifuchem.com

Thumela i-imeyili kithi

Imininingwane Yomkhiqizo

Imikhiqizo Ehlobene

Omaka bomkhiqizo

Incazelo:

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of (S)-2-(Boc-Amino)non-8-Enoic Acid (CAS: 300831-21-4) with high quality, commercial production. Ruifu Chemical offers a wide range of chiral compounds. We can provide Certificate of Analysis (COA), worldwide delivery, small and bulk quantities available. Please contact: alvin@ruifuchem.com

Chemical Properties:

Igama Lekhemikhali	(S)-2-(Boc-Amino)non-8-Enoic Acid
Omqondofana	(S)-2-(tert-Butoxycarbonylamino)non-8-Enoic Acid;(S)-2-(Boc-Amino)-8-Nonenoic Acid;(2S)-2-[(2-Methylpropan-2-yl)oxycarbonylamino]non-8-Enoic Acid;(2S)-2-{[(tert-Butoxy)carbonyl]amino}non-8-Enoic Acid
Inombolo ye-CAS	300831-21-4
Inombolo yeCAT	I-RF-CC347
Isimo Sesitoko	Kukhona kusitoki
I-Molecular Formula	I-C14H25NO4
Isisindo samangqamuzana	271.35
Ukuminyana	1.035±0.06 g/cm3
Ibhrendi	I-Ruifu Chemical

Imininingwane:

Into	Imininingwane
Ukubukeka	Uketshezi Olunsundu
Ukuhlanzeka / Indlela Yokuhlaziya	>98.0% (GC)
ee	>99.0%
Izinga Lokuhlola	I-Enterprise Standard
Ukusetshenziswa	Abaphakathi kweParitaprevir (CAS: 1216941-48-8)

Iphakheji nesitoreji:

Iphakheji: Ibhodlela Elifakwe Fluorinated, 25kg/Drum, noma ngokwezidingo zekhasimende

Isimo Sesitoreji:Gcina ezitsheni ezivaliwe endaweni epholile neyomile;Vikela ekukhanyeni nakumswakama

Izinzuzo:

I-FAQ:

Isicelo:

(S)-2-(Boc-Amino)non-8-Enoic Acid (CAS: 300831-21-4) ingasetshenziswa njengendawo ephakathi ekuhlanganiseni kweParitaprevir (CAS: 1216941-48-8) kanye nama-analog ahlobene.I-Paritaprevir iyisizukulwane sesibili i-NS3/4A protease inhibitor, iyingxenye yokwelashwa kwenhlanganisela yegciwane le-hepatitis C eliphuma ngomlomo, elingena-interferon-free elakhiwe yi-Enanta Pharmaceuticals kanye ne-AbbVie.Ithebhulethi yomthamo ongashintshi we-Paritaprevir, Ombitasvir kanye ne-Ritonavir ethathwe ihlanganiswe ne-Dasabuvir yagunyazelwa ukwelashwa kwe-HCV genotype 1 engapheli e-USA nase-EU ngo-2014, futhi yagunyazwa ukwelapha i-genotype 4 chronic HCV infection ngaphandle kwe-cirrhosis yi-US. I-FDA ngo-2015.